KRAS and cancer: The KRAS G12D inhibitor MRTX1133 has demonstrated potent in vitro and in vivo antitumor efficacy against KRAS G12D-mutant cancer cells in preclinical studies and is now being investigated in a phase I/II multiple expansion cohort trial in patients with advanced solid tumors harboring a KRAS G12D mutation (NCT05737706).